Department of Psychiatry, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0810, USA.
Biomark Med. 2014;8(1):51-7. doi: 10.2217/bmm.13.134.
Numerous biomarkers for somatic disorders are used in routine medical practice. Yet, despite remarkable advances in mental health research, we are not able to identify biomarkers with established clinical utility for mental disorders such as schizophrenia. While identification and characterization of biomarkers are crucial first steps in this process, their predictive diagnostic and treatment utility need to be better developed for clinical practice. The heterogeneity of psychotic disorders etiologically, pathologically and symptomatically presents both a challenge and an opportunity for the use of biomarkers in clinical practice. Simply said, a single biomarker might not exist that necessitates the search for a biomarker profile. In this review we discuss research findings in light of such an approach. We summarize some examples of emerging biomarkers in early psychosis research and delineate how these can be applied to a clinical setting to inform treatment on an individual basis fostering a personalized treatment approach.
在常规医疗实践中，人们使用了许多用于躯体疾病的生物标志物。然而，尽管精神健康研究取得了显著进展，但我们仍无法为精神障碍（如精神分裂症）确定具有既定临床效用的生物标志物。虽然生物标志物的识别和特征描述是这一过程的关键第一步，但它们的预测诊断和治疗效用仍需进一步开发，以应用于临床实践。精神障碍在病因、病理和症状上的异质性既带来了挑战，也为生物标志物在临床实践中的应用提供了机会。简单地说，可能并不存在一个单一的生物标志物，因此需要寻找一个生物标志物谱。在这篇综述中，我们根据这种方法讨论了研究结果。我们总结了一些早期精神病研究中新兴生物标志物的例子，并阐述了如何将这些标志物应用于临床环境，以便根据个体情况提供治疗信息，促进个性化治疗方法。
